Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: J Pharm Biomed Anal. 2013 Apr 9;0:89–98. doi: 10.1016/j.jpba.2013.03.025

Fig. 4.

Fig. 4

Peak areas of belinostat (A) and belinostat glucuronide (B) for a preceding mobile phase (mp) blank injection, a standard curve including blank plasma (bp), and 5 separate mobile phase blank injections displaying the decrease in carryover before a subsequent set of samples is run.